Patent ID: 9617279
Date: 2017-04-11
CPC Classifications: A61K,C07D

Claim:
1. A compound of Formula I: or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein: the dashed line represents an optional double-bond X X X X X X X W is O or S; R R R R is selected from the group consisting of a phenyl ring, a 5-membered heteroaryl ring containing at least one O, N or S atom, or a 6-membered heteroaryl ring, containing at least one nitrogen atom; R R D is a linker, which is selected from a single bond, —O—, —S—, C 1 -C 4 alkylene substituted by 0 to 4 groups independently selected from halo or OH, C 1 -C 4 alkyleneoxy, C 1 -C 4 alkylenethio, C 1 -C 4 alkyleneoxy-C 1 -C 4 -alkylene, C 1 -C 4 -alkylenethio-C 1 -C 4 -alkylene, —S—C 1 -C 4 -alkylene, —O—C 1 -C 4 -alkylene, —NHC(═O)— and —C(═O)NH—, and C 2 -C 6 alkenylene, B is selected from the group consisting of a C R R R alternatively, R 11 and R 12 , when attached to the same nitrogen, combine to form a 4- to 10-membered mono- or bicyclic heterocyclic ring containing carbon atoms substituted by 0 to 3 groups independently selected from the group consisting of halo, cyano, CF 3 , CHF 2 , OCF 3 , OCHF 2 , OCH 2 F, 5- or 6-membered heteroaryl, OH, oxo, hydroxy-C 1 -C 4 -alkyl, C 1 -C 4 alkyl and C 1 -C 4 alkoxy, and 0 to 2 additional heteroatoms selected from N, NR 13 , O and S(O) p ; R R R or R n, at each occurrence, is selected from 0, 1, 2, 3, 4 or 5; and p, at each occurrence, is selected from 0, 1 and 2.